AGE
AgeX Therapeutics, Inc. [AGE] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
AGE Stock Summary
In the News
AGE Financial details
Company Rating
Neutral
Market Cap
27.76M
Income
-17.03M
Revenue
121K
Book val./share
5.07
Cash/share
0.32
Dividend
-
Dividend %
-
Employees
4
Optionable
No
Shortable
Yes
Earnings
13 May 2024
P/E
-0.92
Forward P/E
-
PEG
-0.15
P/S
204.31
P/B
-0.54
P/C
34.69
P/FCF
-2.11
Quick Ratio
0.15
Current Ratio
0.36
Debt / Equity
0.8
LT Debt / Equity
0.13
-
-
EPS (TTM)
-15.78
EPS next Y
-
EPS next Q
-
EPS this Y
38.73%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
3.25%
Revenue last 5Y
-39.33%
Revenue Q/Q
21.74%
EPS Q/Q
-36.13%
-
-
-
-
SMA20
-
SMA50
-7.14%
SMA100
-40.91%
Inst Own
12.19%
Inst Trans
0.98%
ROA
-133%
ROE
75%
ROC
-0.91%
Gross Margin
45%
Oper. Margin
-11208%
Profit Margin
-22299%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
10.902699-35.17
52W High
-68.29%
52W Low
+11%
RSI
43
Rel Volume
0.92
Avg Volume
3.98K
Volume
3.68K
Perf Week
-23.61%
Perf Month
-19.68%
Perf Quarter
-
Perf Half Y
-51.61%
-
-
-
-
Beta
1.187
-
-
Volatility
0.95%, 2.14%
Prev Close
0%
Price
11.1
Change
-11.83%
AGE Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
| Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 1.63 | 1.74 | 0.13 | 0.03 | 0.13 | |
| Net income per share | -11.69 | -10.25 | -9.49 | -9.89 | -13.72 | |
| Operating cash flow per share | -9.59 | -7.3 | -7.29 | -5.5 | -7.23 | |
| Free cash flow per share | -10.19 | -7.32 | -7.29 | -5.5 | -7.23 | |
| Cash per share | 2.22 | 0.49 | 0.54 | 0.6 | 0.32 | |
| Book value per share | 2.09 | -4.78 | -10.98 | -15.95 | 5.07 | |
| Tangible book value per share | 0.44 | -6.52 | -11.83 | -16.73 | 4.4 | |
| Share holders equity per share | 2.09 | -4.78 | -10.98 | -15.95 | 5.07 | |
| Interest debt per share | 1.85 | 5.41 | 13.27 | 19.89 | 8.59 | |
| Market cap | 67.83M | 57.26M | 41.3M | 20.94M | 14.61M | |
| Enterprise value | 67.44M | 63.03M | 53.92M | 38.42M | 18.63M | |
| P/E ratio | -5.48 | -5.22 | -4.04 | -1.96 | -0.99 | |
| Price to sales ratio | 39.26 | 30.65 | 286.81 | 615.93 | 102.88 | |
| POCF ratio | -6.68 | -7.32 | -5.26 | -3.53 | -1.87 | |
| PFCF ratio | -6.28 | -7.31 | -5.26 | -3.53 | -1.87 | |
| P/B Ratio | 30.58 | -11.19 | -3.49 | -1.22 | 2.67 | |
| PTB ratio | 30.58 | -11.19 | -3.49 | -1.22 | 2.67 | |
| EV to sales | 39.03 | 33.74 | 374.44 | 1.13K | 131.19 | |
| Enterprise value over EBITDA | -5.81 | -7.01 | -7.23 | -5.63 | -1.9 | |
| EV to operating cash flow | -6.64 | -8.06 | -6.86 | -6.47 | -2.39 | |
| EV to free cash flow | -6.24 | -8.04 | -6.86 | -6.47 | -2.39 | |
| Earnings yield | -0.18 | -0.19 | -0.25 | -0.51 | -1.01 | |
| Free cash flow yield | -0.16 | -0.14 | -0.19 | -0.28 | -0.53 | |
| Debt to equity | 0.88 | -1.23 | -1.12 | -1.05 | 0.8 | |
| Debt to assets | 0.26 | 1.6 | 4.19 | 5.59 | 0.36 | |
| Net debt to EBITDA | 0.03 | -0.64 | -1.69 | -2.56 | -0.41 | |
| Current ratio | 1.23 | 0.43 | 0.25 | 0.24 | 0.13 | |
| Interest coverage | 0 | 21.38 | -7.33 | -2.09 | -2.03 | |
| Income quality | 0.82 | 0.71 | 0.92 | 0.56 | 0.53 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 4.71 | 3.96 | 46.58 | 175.62 | 65.69 | |
| Research and developement to revenue | 3.42 | 2.66 | 10.11 | 30.15 | 4.25 | |
| Intangibles to total assets | 0.29 | 0.41 | 0.28 | 0.23 | 0.05 | |
| Capex to operating cash flow | 0.06 | 0 | 0 | 0 | 0 | |
| Capex to revenue | -0.37 | -0.01 | 0 | 0 | 0 | |
| Capex to depreciation | -0.67 | -0.01 | 0 | 0 | 0 | |
| Stock based compensation to revenue | 1.1 | 0.5 | 6.94 | 22.35 | 4.56 | |
| Graham number | 23.46 | 33.19 | 48.42 | 59.59 | 39.55 | |
| ROIC | -2.76 | -8.92 | -6.99 | -7.76 | -1.01 | |
| Return on tangible assets | -2.34 | -4.7 | -4.47 | -4.26 | -1.3 | |
| Graham Net | -2.08 | -7.98 | -13.39 | -18.45 | -5.76 | |
| Working capital | 757K | -3.07M | -6.73M | -7.63M | -5.16M | |
| Tangible asset value | 466K | -6.99M | -12.75M | -18.05M | 4.75M | |
| Net current asset value | -771K | -7.04M | -12.8M | -18.1M | -5.85M | |
| Invested capital | 0.88 | -1.23 | -1.12 | -1.05 | 0.8 | |
| Average receivables | 247K | 344.5K | 175.5K | 14.5K | 30.5K | |
| Average payables | 1.37M | 1.37M | 1.1M | 902.5K | 1.22M | |
| Average inventory | 0 | 0.5 | 0.5 | 0 | 0 | |
| Days sales outstanding | 76.68 | 63.7 | 63.37 | 42.94 | 146.51 | |
| Days payables outstanding | 1.97K | 3.3K | 14.81K | 29.03K | 3.02K | |
| Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
| Receivables turnover | 4.76 | 5.73 | 5.76 | 8.5 | 2.49 | |
| Payables turnover | 0.18 | 0.11 | 0.02 | 0.01 | 0.12 | |
| Inventory turnover | 0 | 158K | 0 | 0 | 0 | |
| ROE | -5.58 | 2.15 | 0.86 | 0.62 | -2.71 | |
| Capex per share | -0.6 | -0.02 | 0 | 0 | 0 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
| Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0.01 | 0.01 | 0.01 | 0.04 | 0.05 | |
| Net income per share | -2.51 | -5.1 | -2.47 | -5.01 | -3.2 | |
| Operating cash flow per share | -1.22 | -1.73 | -1.87 | -1.73 | -1.9 | |
| Free cash flow per share | -1.22 | -1.73 | -1.87 | -1.73 | -1.9 | |
| Cash per share | 0.6 | 0.26 | 0.24 | 0.37 | 0.32 | |
| Book value per share | -15.95 | -18.44 | -20.55 | -25.52 | 5.07 | |
| Tangible book value per share | -16.73 | -19.19 | -21.29 | -26.21 | 4.4 | |
| Share holders equity per share | -15.95 | -18.44 | -20.55 | -25.52 | 5.07 | |
| Interest debt per share | 17.7 | 28.87 | 31.33 | 4.87 | 4.02 | |
| Market cap | 20.94M | 25.16M | 33.89M | 25.81M | 14.61M | |
| Enterprise value | 38.42M | 54.94M | 66.64M | 27.63M | 18.63M | |
| P/E ratio | -1.94 | -1.14 | -3.17 | -1.19 | -1.06 | |
| Price to sales ratio | 2.62K | 2.52K | 3.77K | 561.12 | 260.89 | |
| POCF ratio | -15.85 | -13.49 | -16.79 | -13.85 | -7.12 | |
| PFCF ratio | -15.85 | -13.49 | -16.79 | -13.85 | -7.12 | |
| P/B Ratio | -1.22 | -1.26 | -1.53 | -0.94 | 2.67 | |
| PTB ratio | -1.22 | -1.26 | -1.53 | -0.94 | 2.67 | |
| EV to sales | 4.8K | 5.49K | 7.4K | 600.73 | 332.67 | |
| Enterprise value over EBITDA | -22.02 | -25.89 | -36.02 | -11.91 | -5.28 | |
| EV to operating cash flow | -29.09 | -29.46 | -33.01 | -14.82 | -9.08 | |
| EV to free cash flow | -29.09 | -29.46 | -33.01 | -14.82 | -9.08 | |
| Earnings yield | -0.13 | -0.22 | -0.08 | -0.21 | -0.24 | |
| Free cash flow yield | -0.06 | -0.07 | -0.06 | -0.07 | -0.14 | |
| Debt to equity | -1.05 | -1.51 | -1.49 | -0.08 | 0.8 | |
| Debt to assets | 5.59 | 2.4 | 2.69 | 0.18 | 0.36 | |
| Net debt to EBITDA | -10.02 | -14.03 | -17.7 | -0.79 | -1.14 | |
| Current ratio | 0.24 | 0.08 | 0.06 | 0.36 | 0.13 | |
| Interest coverage | -1.82 | -1.96 | -2.38 | -0.78 | 127.14 | |
| Income quality | 0.48 | 0.57 | 0.75 | 0.35 | 0.59 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 197.63 | 199.3 | 192.22 | 47.22 | 61.3 | |
| Research and developement to revenue | 26 | 17.4 | 17.78 | 4.74 | 2.66 | |
| Intangibles to total assets | 0.23 | 0.06 | 0.05 | 0.05 | 0.05 | |
| Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
| Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
| Capex to depreciation | 0 | 0 | 0 | 0 | 0 | |
| Stock based compensation to revenue | 14.25 | 7 | 3.89 | 0.87 | 8.98 | |
| Graham number | 29.99 | 46 | 33.82 | 53.61 | 19.11 | |
| ROIC | -1.91 | -0.36 | -0.23 | 0.15 | -0.36 | |
| Return on tangible assets | -1.08 | -0.47 | -0.23 | -0.47 | -0.3 | |
| Graham Net | -18.45 | -29.89 | -31.79 | -36.52 | -5.76 | |
| Working capital | -7.63M | -20.78M | -23.16M | -2.06M | -5.16M | |
| Tangible asset value | -18.05M | -20.71M | -22.97M | -28.29M | 4.75M | |
| Net current asset value | -18.1M | -30.79M | -33.22M | -38.71M | -5.85M | |
| Invested capital | -1.05 | -1.51 | -1.49 | -0.08 | 0.8 | |
| Average receivables | 2.5K | 5K | 6K | 38.5K | 64K | |
| Average payables | 726.5K | 1.05M | 884K | 839K | 1.29M | |
| Average inventory | 0 | 0 | 0 | 0 | 0 | |
| Days sales outstanding | 45 | 54 | 60 | 138.91 | 91.61 | |
| Days payables outstanding | 75.69K | 113.58K | 9.11K | 3.2K | 3.74K | |
| Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
| Receivables turnover | 2 | 1.67 | 1.5 | 0.65 | 0.98 | |
| Payables turnover | 0 | 0 | 0.01 | 0.03 | 0.02 | |
| Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
| ROE | 0.16 | 0.28 | 0.12 | 0.2 | -0.63 | |
| Capex per share | 0 | 0 | 0 | 0 | 0 |
AGE Frequently Asked Questions
What is AgeX Therapeutics, Inc. stock symbol ?
AgeX Therapeutics, Inc. is a US stock , located in Alameda of Ca and trading under the symbol AGE
What is AgeX Therapeutics, Inc. stock quote today ?
AgeX Therapeutics, Inc. stock price is $11.1 today.
Is AgeX Therapeutics, Inc. stock public?
Yes, AgeX Therapeutics, Inc. is a publicly traded company.
Company Profile
- Volume Average 3.98K
- Market Capitalization 27.76M
- Employee 4
- CEO Ms. Eun-Jae Park CPA
- Headquarters Alameda,CA,US
- IPO Date 2018-11-29
-
Website
https://www.agexinc.com 
AgeX Therapeutics, Inc., a biotechnology company, focuses on the development and commercialization of novel therapeutics targeting human aging and degenerative diseases in the United States. The company's lead cell-based therapeutic candidates in development include AGEX-BAT1, a cell therapy product candidate for the treatment of various age-related metabolic disorders, such as Type II adult-onset diabetes and obesity; and AGEX-VASC1, a cell-based therapy to restore vascular support in aged ischemic tissues, such as peripheral vascular disease and ischemic heart disease. Its lead drug-based therapeutic candidate for scarless wound repair in discovery is AGEX-iTR1547, a drug-based formulation; and lead biologic candidate for induced tissue regeneration is AGEX-iTR1550, a gene delivery technology. The company has a research collaboration with the University of California at Irvine to develop cellular therapies to treat neurological disorders and diseases. AgeX Therapeutics, Inc. was incorporated in 2017 and is based in Alameda, California.
